Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline Educational Activity

The dramatic increase in the prevalence of individuals at risk for the development of ASCVD and T2DM throughout the developed and developing world requires that physicians and other care providers are aware of the risk factors for these conditions and can identify individuals at risk in order to initiate treatment to prevent these diseases. The Endocrine Society has recognized the importance of identifying individuals who are at metabolic risk so that efforts can be instituted to prevent both ASCVD and T2DM.

Several risk factors for ASCVD and T2DM—hypertension, lipid abnormalities, hyperglycemia, and abdominal adiposity—tend to cluster together. This clustering was originally known as the insulin resistance syndrome (IRS) because it was thought that insulin resistance was its underlying cause. However, although insulin resistance may be associated with these risk factors, it may not always be present and does not fully explain the syndrome. The term IRS has been replaced by combinations of clinical criteria that are defined differently by various organizations and attempt to describe a clinical entity, the metabolic syndrome. The major purpose was to use clinical signs and symptoms to identify people who have a combination of risk factors that contribute to a higher long-term risk for ASCVD and T2DM than that in the general population.

The recent updated Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline addresses the population of individuals with components of the metabolic syndrome who do not yet have diagnosed ASCVD or T2DM and the steps that can be taken to prevent these two diseases.

This short case-based online activity allows you to apply these recommendations to practice.

Target Audience

This content is for physicians and healthcare professionals seeking to remain up to date on the latest recommendations made by the Society for endocrine treatment of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk.

Learning Objectives

Apply the clinical practice guideline recommendations for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes mellitus (T2DM) in individuals at metabolic risk for developing these conditions.

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credits
  • 0.50 CME Certificate of Participation
Course opens: 
07/01/2019
Course expires: 
07/31/2021
Rating: 
0

FACULTY

Lars F. Berglund, MD, PhD
University of California, Davis

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationship(s):

Lars F. Berglund, MD, PhD owns stocks with Boston Scientific, Gilead Schiences, Johnson & Johnson, Medtronic, Novo Nordisk, and Pfizer.

The medical editor for this program, Abbie L. Young, MS, CGC, ELS(D), reported no relevant financial relationships.

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMERS

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

USE OF PROFESSIONAL JUDGMENT:

The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

This activity is not supported by educational grant(s) or other funds from any commercial supporter.

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
 

The Endocrine Society designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Expiration Date

July 31, 2021 (date after which this enduring material is no longer certified for AMA PRA Category 1 Credits)

Available Credit

  • 0.50 AMA PRA Category 1 Credits
  • 0.50 CME Certificate of Participation

Accreditation Period

Course opens: 
07/01/2019
Course expires: 
07/31/2021

This course is complimentary and available to everyone. Please click START to enroll and begin. To claim CME, you must be logged in. If you already have an account please login. If you do not have an account, you may create a complimentary account on the login page.